Patent ID: 9663579
Date: 2017-05-30
CPC Classifications: A61K,A61P,C07K

Claim:
1. A method for achieving clinical response of Crohn's disease in a human patient, comprising intravenously administering to a human patient with Crohn's disease, wherein said human patient had a lack of an adequate response with, lost response to, or was intolerant to a TNFα antagonist: a first dose of 300 mg of an antibody that has binding specificity for human α4β7 integrin, a second dose of 300 mg of the antibody two weeks after the first dose, and a third dose of 300 mg of the antibody six weeks after the first dose, wherein the antibody comprises the heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO:2, and the light chain variable region sequence of amino acids 20 to 131 of SEQ ID NO:4.